

IHCP *banner page*

INDIANA HEALTH COVERAGE PROGRAMS

BR201918

APRIL 30, 2019

IHCP to update pricing for certain physician-administered drug codes

Effective May 30, 2019, the Indiana Health Coverage Programs (IHCP) will update pricing for the Healthcare Common Procedure Coding System (HCPCS) physician-administered drug (PAD) codes in Table 1. Pricing for these codes is changing from maximum-fee pricing to manual pricing, and will follow standard IHCP reimbursement methodology for PADs. The detail would pay 105% of the wholesale acquisition cost (WAC) of the National Drug Code (NDC) billed. This pricing change applies to claims with dates of service (DOS) on or after May 30, 2019.

The procedure codes in Table 1, which are required to be billed with NDCs, have no active NDCs from a rebating manufacturer (at the time of this banner page publication). If an active, "rebateable" NDC becomes available in the future for a procedure code in Table 1, the IHCP will determine whether a new maximum-fee rate, instead of manual pricing, should be established for the code.

This pricing and reimbursement information applies to services delivered under the fee-for-service (FFS) delivery system. Individual managed care entities (MCEs) establish and publish reimbursement information within the managed care delivery system. Questions about managed care should be directed to the MCE with which the member is enrolled.

This pricing change will be reflected in the next regular update to the *Professional Fee Schedule* and to the *Outpatient Fee Schedule*, accessible from the [IHCP Fee Schedules](#) page at in.gov/medicaid/providers.

For more information about billing NDCs and PAD codes, see the [Claim Submission and Processing](#) provider reference module, and the [Injections, Vaccines, and Other Physician-Administered Drugs](#) module at in.gov/medicaid/providers. The latter reference also contains details about reimbursement and the Medicaid Drug Rebate Program.



Table 1- HCPCS codes updated from maximum-fee pricing to manual pricing, effective for DOS on or after May 30, 2019

Procedure code	Description
J0120	Injection, tetracycline, up to 250 mg
J0190	Injection, biperiden lactate, per 5 mg
J0200	Injection, alatrofloxacin mesylate, 100 mg

continued

*Table 1- HCPCS codes updated from maximum-fee pricing to manual pricing,
effective for DOS on or after May 30, 2019 (continued)*

Procedure code	Description
J0205	Injection, alglucerase, per 10 units
J0215	Injection, alefacept, 0.5 mg
J0288	Injection, amphotericin B cholesteryl sulfate complex, 10 mg
J0350	Injection, anistreplase, per 30 units
J0365	Injection, aprotonin, 10,000 kiu
J0380	Injection, metaraminol bitartrate, per 10 mg
J0390	Injection, chloroquine hydrochloride, up to 250 mg
J0395	Injection, arbutamine HCl, 1 mg
J0400	Injection, aripiprazole, intramuscular, 0.25 mg
J0520	Injection, bethanechol chloride, Myotonachol or Urecholine, up to 5 mg
J0620	Injection, calcium glycerophosphate and calcium lactate, per 10 ml
J0710	Injection, cephapirin sodium, up to 1 gm
J0715	Injection, ceftizoxime sodium, per 500 mg
J0745	Injection, codeine phosphate, per 30 mg
J0840	Injection, crotalidae polyvalent immune fab (ovine), up to 1 gram
J0890	Injection, peginesatide, 0.1 mg (for ESRD on dialysis)
J0945	Injection, brompheniramine maleate, per 10 mg
J1094	Injection, dexamethasone acetate, 1 mg
J1180	Injection, dyphylline, up to 500 mg
J1260	Injection, dolasetron mesylate, 10 mg
J1320	Injection, amitriptyline HCl, up to 20 mg
J1330	Injection, ergonovine maleate, up to 0.2 mg
J1435	Injection, estrone, per 1 mg
J1436	Injection, etidronate disodium, per 300 mg
J1457	Injection, gallium nitrate, 1 mg
J1600	Injection, gold sodium thiomalate, up to 50 mg
J1655	Injection, tinzaparin sodium, 1000 IU
J1675	Injection, histrelin acetate, 10 micrograms

continued

Table 1- HCPCS codes updated from maximum-fee pricing to manual pricing, effective for DOS on or after May 30, 2019 (continued)

Procedure code	Description
J1700	Injection, hydrocortisone acetate, up to 25 mg
J1710	Injection, hydrocortisone sodium phosphate, up to 50 mg
J1730	Injection, diazoxide, up to 300 mg
J1810	Injection, droperidol and fentanyl citrate, up to 2 ml ampule
J1835	Injection, itraconazole, 50 mg
J1840	Injection, kanamycin sulfate, up to 500 mg
J1850	Injection, kanamycin sulfate, up to 75 mg
J1945	Injection, lepirudin, 50 mg
J1960	Injection, levorphanol tartrate, up to 2 mg
J1990	Injection, chlordiazepoxide HCl, up to 100 mg
J2180	Injection, meperidine and promethazine HCl, up to 50 mg
J2320	Injection, nandrolone decanoate, up to 50 mg
J2355	Injection, oprelvekin, 5 mg
J2460	Injection, oxytetracycline HCl, up to 50 mg
J2513	Injection, pentastarch, 10% solution, 100 ml
J2650	Injection, prednisolone acetate, up to 1 ml
J2670	Injection, tolazoline HCl, up to 25 mg
J2725	Injection, protirelin, per 250 mcg
J2805	Injection, sincalide, 5 micrograms
J2850	Injection, secretin, synthetic, human, 1 microgram
J2910	Injection, aurothioglucose, up to 50 mg
J2940	Injection, somatrem, 1 mg
J2950	Injection, promazine HCl, up to 25 mg
J2995	Injection, streptokinase, per 250,000 IU
J3265	Injection, torsemide, 10 mg/ml
J3280	Injection, thiethylperazine maleate, up to 10 mg
J3302	Injection, triamcinolone diacetate, per 5 mg
J3303	Injection, triamcinolone hexacetonide, per 5 mg
J3305	Injection, trimetrexate glucuronate, per 25 mg
J3310	Injection, perphenazine, up to 5 mg

continued

Table 1- HCPCS codes updated from maximum-fee pricing to manual pricing, effective for DOS on or after May 30, 2019 (continued)

Procedure code	Description
J3320	Injection, spectinomycin dihydrochloride, up to 2 gm
J3350	Injection, urea, up to 40 gm
J3364	Injection, urokinase, 5000 IU vial
J3365	Injection, IV, urokinase, 250,000 IU vial
J3400	Injection, triflupromazine HCl, up to 20 mg
J3520	Edetate disodium, per 150 mg
J7110	Infusion, dextran 75, 500 ml
J7306	Levonorgestrel (contraceptive) implant system, including implants and supplies
J7309	Methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 gram
J7310	Ganciclovir, 4.5 mg, long-acting implant
J7505	Muromonab-CD3, parenteral, 5 mg
J7513	Daclizumab, parenteral, 25 mg
J7665	Mannitol, administered through an inhaler, 5 mg
J7674	Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg
J9020	Injection, asparaginase, not otherwise specified, 10,000 units
J9033	Injection, bendamustine HCl (Treanda), 1 mg
J9098	Injection, cytarabine liposome, 10 mg
J9160	Injection, denileukin difitox, 300 micrograms
J9165	Injection, diethylstilbestrol diphosphate, 250 mg
J9203	Injection, gemtuzumab ozogamicin, 0.1 mg
J9212	Injection, interferon alfacon-1, recombinant, 1 microgram
J9213	Injection, interferon, alfa-2a, recombinant, 3 million units
J9215	Injection, interferon, alfa-N3, (human leukocyte derived), 250,000 IU
J9219	Leuprolide acetate implant, 65 mg
J9270	Injection, plicamycin, 2.5 mg
J9600	Injection, porfimer sodium, 75 mg
Q0174	Thiethylperazine maleate, 10 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Q0515	Injection, sermorelin acetate, 1 microgram

QUESTIONS?

If you have questions about this publication, please contact Customer Assistance at 1-800-457-4584.

COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from the [Banner Pages](#) page of the IHCP provider website at in.gov/medicaid/providers.

TO PRINT

A [printer-friendly version](#) of this publication, in black and white and without photos, is available for your convenience.

SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the [IHCP provider website](#) at in.gov/medicaid/providers.

